Cancer Immunotherapy Consortium 2013 Scientific Colloquium

Washington, District of Columbia
CIC Colloq 2013
About the 2013 Scientific Colloquium

The development of combination treatments is widely viewed by both industry and academia to be the critical path to unlocking the full promise of cancer immunotherapies. Despite this widespread consensus, the complexity of developing combination cancer immunotherapies presents several challenges. With so many treatments targeting different immune pathways and mechanisms, how do you select which ones to bring together? How do you minimize the risks to companies and patients when testing two or more experimental agents in combination? And what tools need to be incorporated into clinical trial designs to enable combination immunotherapies to be tested more rapidly, cost-effectively, and in a way that provides sufficient data to assess clinical benefit and inform future development decisions? The 2013 Scientific Colloquium of the CRI Cancer Immunotherapy Consortium, Entering the Era of Combination Therapies: Practical Implementation, will bring together leaders from the regulatory, scientific, and business communities to present new methodological tools, leading-edge scientific data from ongoing combination studies, and innovative models of academic-industry collaboration that are helping to overcome these and other challenges to optimizing combination cancer therapies for the benefit of patients.

Special thanks to our meeting sponsors:

 
  
  
 
  
Meeting Organizers
  • James Allison, The University of Texas MD Anderson Cancer Center
  • Neil Berinstein, Ontario Institute for Cancer Research
  • Mark Frohlich, Dendreon Corporation
  • Axel Hoos, GlaxoSmithKline
  • Hyam I. Levitsky, Roche and Johns Hopkins School of Medicine
  • Israel Lowy, Regeneron Pharmaceuticals
  • Jens-Peter Marschner, Merck KGaA
  • Kunle Odunsi, Roswell Park Cancer Institute
  • Gerd Ritter, Ludwig Institute for Cancer Research
  • Pramod Srivastava, University of Connecticut School of Medicine
  • Kerry Wentworth, Agenus Inc.
  • Jedd D. Wolchok, Memorial Sloan-Kettering Cancer Center
About the Cancer Immunotherapy Consortium

The Cancer Immunotherapy Consortium (CIC), a program of the US-based nonprofit Cancer Research Institute, is an international association of pharmaceutical and biotechnology companies and academic institutions that share a common interest in immunotherapy research and development. CIC's mission is to improve patient care by making cancer immunotherapies part of the standard-of-care in oncology. CIC acts as a single and powerful voice within the biomedical research community and provides a platform that allows its stakeholders to advance the field by working together to achieve solutions to scientific and developmental challenges.

About the Cancer Research Institute

The Cancer Research Institute was founded in 1953 to foster the science of cancer immunology. It is the world's only nonprofit organization dedicated exclusively to the support and coordination of laboratory and clinical efforts that will lead to the immunological treatment, control, and prevention of cancer. As the initiator and steward of unprecedented global scientific and clinical collaboration, the Cancer Research Institute is ushering a new era of scientific progress, hastening the discovery of effective cancer vaccines and other immune-based therapies that are providing new hope to patients.
 

Contact Information

Payment Instructions

  • The Early Registration Deadline is Friday, March 22, 2013. Registration rates will increase after this date.

    All major credit cards are accepted. If you are paying by check, please make checks payable to Cancer Research Institute. (U.S. funds drawn on U.S. banks only.) Mail a copy of your registration information with your check to:

    2013 CIC Colloquium
    Cancer Research Institute
    One Exchange Plaza
    55 Broadway, Suite 1802
    New York, NY 10006

    Requests for refunds must be submitted in writing by Friday, March 29, 2013 to meetings@cancerresearch.org. Refund requests received after that date will not be honored. There will be a $100 processing fee for all refunds. Registrations are non-transferable.